# Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.

> **NCT05266300** · — · COMPLETED · sponsor: **University of Southern Denmark** · enrollment: 722 (actual)

## Conditions studied

- Adverse Drug Event
- Colon Cancer
- Breast Cancer
- Pancreas Cancer
- Rectal Cancer
- Gastric Cancer
- Oesophageal Cancer
- Bile Duct Cancer

## Interventions

- **GENETIC:** DPYD genotype

## Key facts

- **NCT ID:** NCT05266300
- **Lead sponsor:** University of Southern Denmark
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-10-01
- **Target enrollment:** 722 (ACTUAL)
- **Last updated:** 2022-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266300, "Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT05266300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*